Last reviewed · How we verify
Divalproex Sodium Extended-Release Tablets
At a glance
| Generic name | Divalproex Sodium Extended-Release Tablets |
|---|---|
| Sponsor | Virginia Commonwealth University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)? (PHASE4)
- Effect of Adding Lamotrigine to Sodium Valproate in Childhood Epilepsy: Clinicolabratory Study (PHASE4)
- Combination Regimen With Sodium Valproate for Severe Hemophilia: a Single-arm, Phase 1, Pilot Trial. (PHASE1, PHASE2)
- Bioavailability and Food Effect of Sodium Valproate Minitablets in Healthy Subjects. (PHASE1)
- Bioequivalence Study of Sodium Valproate and Valproic Acid Tablets (PHASE4)
- Compliance With Once-Daily Divalproex Extended-Release Tablets (Depakote-ER) Versus Multiple-Daily Dose Valproic Acid Capsules (Depakene) in Epilepsy:
- Treatment of Mania Symptoms With Drug Therapy (PHASE3)
- Tolerability and Efficacy of Depakote-extended Release in the Elderly (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: